Newsroom

News

BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria, announced today that it has established a long-term research collaboration with the prestigious European institute, Helmholtz Centre for Infection Research (HZI) and its site Helmholtz Institute for Pharmaceutical Research Saarland (HIPS).

23.01.2024

HIPS

Group photo of the HIRI scientists involved in the study

News

To combat viruses, bacteria and other pathogens, synthetic biology offers new technological approaches whose performance is being validated in experiments. Researchers from the Würzburg Helmholtz Institute for RNA-based Infection Research and the Helmholtz AI Cooperative applied data integration and artificial intelligence (AI) to develop a machine learning approach that can predict the efficacy of CRISPR technologies more accurately than before. The findings were published today in the journal Genome Biology.

11.01.2024

HIRI

Decorative image to represent the new databases

News

Modern pharmaceutical research generates large amounts of data faster than ever before. To analyze and evaluate this data, it is collected and structured in extensive databases and thus provides the basis for the development of new active ingredients. Researchers at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) have now published two such databases. While the "ABC-HuMi" database focuses on genetic data from microorganisms that colonize humans, "ZEBRA" provides a high-resolution cell atlas of the human and mouse brain. Both databases were published in the annual database issue of the journal Nucleic Acids Research.

09.01.2024

HIPS

News

Despite the end of the pandemic, COVID-19 continues to pose a serious health threat. Most individuals have established robust immune protection and do not develop severe disease but the infection can still lead to marked and sometimes long-lasting disease symptoms. In the late summer of 2023 a new SARS-CoV-2 variant emerged, BA.2.86 (Pirola), which, based on genetics, differs markedly from all previously circulating variants.

09.01.2024

HZI Campus

Group Picture of Participants of the ENLIGHT-TEN+ Winter School

News

From 13 to 17 November 2023, 28 young scientists gathered at BAYER in Berlin to take part in the Winter School for Translational Medical Research and Drug Development organized by ENLIGHT-TEN+ and EATRIS. Experts from science and industry provided in-depth insights into the basics of drug production and introduced the young scientists to the processes through interactive exercises and case studies. BAYER is a member of the ENLIGHT-TEN+ consortium and was primarily responsible for organizing the Winter School.

21.12.2023

HZI Campus

Story

Vaccinations do not always live up to what we would want them to do – so far, anyway. But they are still invaluable for our health and life in our communities.

12.12.2023

HZI Campus

Back to the first page
...
29
30
31
32
...
149

HZI in the media

Medikament Tolcapon identifiziert. Das HIPS ist ein Standort des Helmholtz-Zentrums für Infektionsforschung (HZI) in Kooperation ...

01.12.2025

Homburg

... wissenschaftlicher Ko-Direktor des Helmholtz Zentrums für Infektionsforschung (HZI). Thomas Pietschmann engagiert sich seit 2023 im ...

28.11.2025

juraforum.de

Dr. Alexander Titz, group leader at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS). “Finding new ways to disrupt its

28.11.2025

ARCHYDE

... “, sagte die Leiterin der Epidemiologie am Braunschweiger Helmholtz-Zentrum für Infektionsforschung.

Lange betonte, flächendeckende ...

28.11.2025

Evangelische Zeitung

... ein Zentrum für Quantentechnologie entstehen und das Helmholtz-Institut für Pharmazeutische Forschung ausgebaut werden.

Mehr ...

27.11.2025

Tagesschau

Euro werden investiert in die Erweiterung des Helmholtz-Instituts für Pharmazeutische Forschung Saarland (HIPS). Und ...

27.11.2025

ZEIT online

s drug tolcapone. HIPS is a site of the Helmholtz Center for Infection Research (HZI) in collaboration with Saarland University.

The

26.11.2025

Medical Xpress

... erhielt das Projekt „Citrapeutics“ vom Helmholtz-Zentrum für Infektionsforschung (HZI) in Braunschweig eine Förderung in Höhe ...

25.11.2025

Bionity.COM

led by Hannover Medical School (MHH) and the Helmholtz Center for Infection Research (HZI) has now discovered clear molecular signatures for

24.11.2025

Medical Xpress

Medizinischen Hochschule Hannover (MHH) und dem Helmholtz-Zentrum für Infektionsforschung (HZI), hat nun eindeutige molekulare Signaturen ...

24.11.2025

DeutschesGesundheitsPortal

Braunschweig. Das Helmholtz-Zentrum für Infektionsforschung (HZI) bringt anlässlich seines 60. Jubiläums seine Forschung vom 3. ...

22.11.2025

Regional Heute

Universität Hannover (LUH), dem Helmholtz Zentrum für Infektionsforschung (HZI) in Braunschweig, der Technischen Universität Braunschweig ...

21.11.2025

Medizinische Hochschule Hannover

Register now for the HZI-Newsletter

and stay up to date!

Email address *

We use rapidmail to send our newsletter. I agree that my data entered here will be transmitted to rapidmail. I have taken note of the HZI's privacy policy and have been informed of my rights.